Last updated: 5 months ago
NLS Pharmaceutics Ltd. 6-K/A Report: Correction on Extraordinary Shareholders’ Meeting Date
NLS Pharmaceutics Ltd. filed Amendment No. 1 to Form 6-K, correcting the record date for the January 2025 Extraordinary Shareholders’ Meeting. Key SEC compliance details included.